

07691OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**RECEIVED**

Atty. Docket No. 07691.0009	Serial No. 09/580,491
Applicant Kurt HERTOGS et al.	
Filing Date May 30, 2000	Group: 1631

MAY 02 2001
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS


Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
NG	5,856,086	01/05/99	Kozal et al.			
	5,650,268	07/22/97	Kozal et al.			
	5,631,128	05/20/97	Kozal et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
NG	WO 00/78996 A1	12/28/00	PCT			yes
	WO 99/67427	12/29/99	PCT			yes
	WO 99/61658	12/02/99	PCT			yes
	WO 99/61666	12/02/99	PCT			yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NG	Balotta et al., "Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in <i>pol</i> Reverse Transcriptase and Protease Region: Outcome After Treatment in Recently Infected Individuals," <i>Antiviral Therapy</i> , 5, pp. 7-14 (2000).
	Been-Tiktak et al., "In-Vitro Selection of HIV-1 Variants Resistant to Non-Nucleoside Reverse Transcriptase Inhibitors in Monocyte-Derived Macrophages," <i>Journal of Antimicrobial Chemotherapy</i> , 40, pp. 847-853 (1997).
	Catucci et al., "Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy with Lamivudine, Zidovudine, and Protease Inhibitors," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 21, pp. 203-208 (1999).
	Coakley et al., "Phenotypic and Genotypic Resistance Patterns of HIV-1 Isolates Derived from Individuals Treated with Didanosine and Stavudine," <i>AIDS</i> , 14, pp. F9-F15 (2000).
	Descamps et al., "Susceptibility of Human Immunodeficiency Virus Type 1 Group O Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analyses," <i>Journal of Virology</i> , pp. 8893-8898 (1997).
	Edelstein et al., "Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 <i>pol</i> Gene That are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine," <i>Journal of Clinical Microbiology</i> , pp. 569-572 (1998).

**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)**RECEIVED**

Atty. Docket No.	09/580,491	Serial No.	09/580,491
Applicant	Kurt HERTOGS et al.		
Filing Date	May 30, 2000	Group:	1631

MAY 02 2001

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Gunthard et al., "Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes After a Year of Potent Antiretroviral Therapy," <i>Journal of Virology</i> , pp. 2422-2428 (1998).
	Holodniy et al., "Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype," <i>The Journal of Infectious Diseases</i> , 174, pp. 854-857 (1996).
	Hsu et al., Higher Fidelity of RNA-Dependent DNA Mispair Extension by M184V Drug-Resistant than Wild-type Reverse Transcriptase of Human Immunodeficiency Virus Type 1," <i>Nucleic Acids Research</i> , 25(22), pp. 4532-4536 (1997).
	Ives et al., "Emergence of Resistant Variants of HIV <i>in vitro</i> During Monotherapy with the Proteinase Inhibitor Saquinavir," <i>Journal of Antimicrobial Chemotherapy</i> , 39, pp. 771-779 (1997).
	Kellam et al., "Fifth Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Contributes to the Development of High-Level Resistance to Zidovudine," <i>Proc. Natl. Acad. Sci. USA</i> , 89, pp. 1934-1938 (1992).
	Kemp et al., "A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2', 3'-Dideoxy-3'-Thiacytidine," <i>Journal of Virology</i> , 72, pp. 5093-5098 (1998).
	Larder et al., "Tipranavir Inhibits Broadly Protease Inhibitor-Resistant HIV-1 Clinical Samples," <i>AIDS</i> , 14, pp. 1943-1948 (2000).
	Mohamed et al. "The Sequential Occurrence of <i>pol</i> 215 and <i>pol</i> 41 Zidovudine Resistance Mutations is Associated in an Additive Fashion with Low CD4 Cell Counts and High Plasma and Cellular HIV Viral Load," <i>Antiviral Research</i> , 39, pp. 47-53 (1998).
	Moyle, "Viral Resistance Patterns Selected by Antiretroviral Drugs and Their Potential to Guide Treatment Choice," <i>Exp. Opin. Invest. Drugs</i> , 6(8), pp. 943-964 (1997).
	Nakano et al., "Clonal Selection of HIV Type 1 Variants Associated with Resistance to Foscarnet <i>in Vitro</i> : Confirmation by Molecular Evolutionary Analysis," <i>Aids Research and Human Retroviruses</i> , 13(7), pp. 563-573 (1997).
	Schmidt et al., "Simple Algorithm Derived from a Geno-/Phenotypic Database to Predict HIV-1 Protease Inhibitor Resistance," <i>AIDS</i> , 14, pp. 1731-1738 (2000).
	Shafer et al., "Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database," <i>Nucleic Acids Research</i> , 28(1), pp. 346-348 (2000).
	Tamalet et al., "Multidrug Resistance Genotypes (Insertions in the β 3- β 4 Finger Subdomain and MDR Mutations) of HIV-1 Reverse Transcriptase from Extensively Treated Patients: Incidence and Association with Other Resistance Mutations," <i>Virology</i> , 270, pp. 310-316 (2000).
	Villahermosa et al., "Evaluation of Mixtures of Wild-Type HIV-1 and HIV-1 with Resistance Point Mutations Against Reverse Transcriptase Inhibitors," <i>Antiviral Therapy</i> , 3, pp. 221-227 (1998).



07691OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	07691-0009	Serial No.	09/580,491
Applicant	Kurt HERTOGS et al.		
Filing Date	May 30, 2000	Group:	1631

<i>Wt</i>	Wegner et al., "Prevalence of Genotypic and Phenotypic Resistance to Anti-Retroviral Drugs in a Cohort of Therapy-Naïve HIV-1 Infected US Military Personnel," <i>AIDS</i> , 14, pp. 1009-1015 (2000).		
Examiner	<i>Nikolai N Galsky</i>	Date Considered	<i>12-03-01</i>
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	